NERV
Minerva Neurosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.43
−5.54%Aug 7, 2026, 00:00 UTC
Minerva Neurosciences reported Q2 2026 results with a net loss of $17.5 million and diluted EPS of -$0.14, including $7.2 million in R&D expenses and $3.5 million in G&A expenses.